Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Illumina

Evaluate

Thumbnail
June 12, 2023

Illumina’s divestment of Grail creeps closer

Thumbnail
April 28, 2023

Quest makes hay for $300m

Article image
Vantage logo
March 15, 2023

Illumina investors give long reads short shrift

Article image
Vantage logo
December 06, 2022

Illumina loses its grip

The sequencing giant’s acquisition of Grail is heading for the rocks.

Article image
Vantage logo
October 14, 2022

Medtech bleeds corporate venture cash

Overall venture investment in the sector remains steady, but the big strategics back off.

Article image
Vantage logo
September 30, 2022

Investors shrug off Illumina’s $200 genome

Article image
Vantage logo
September 29, 2022

Ember burns bright for Angle

A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.

Article image
Vantage logo
September 12, 2022

Esmo 2022 – Exact trails Grail on sensitivity

Article image
Vantage logo
September 08, 2022

Esmo 2022 – Galleri’s real-world exhibition disappoints

Grail finds the path for its liquid biopsy less clear than it might have hoped.

Article image
Vantage logo
September 06, 2022

The outlook darkens for Illumina

Article image
Vantage logo
September 02, 2022

Illumina wins in the US but fears a loss in Europe

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up